Most companies do not need to hire a dedicated, full-time quality manager solely to implement MDCG 2019-11. The guidance focuses on clinical evaluation and post-market clinical follow-up, which can often be managed through existing quality systems, consultants, or part-time specialists. The decision depends on your company\u2019s size, product complexity, and current quality management capabilities.<\/p>\n
MDCG 2019-11<\/strong> is a guidance document that provides detailed expectations for clinical evaluation and post-market clinical follow-up under the Medical Device Regulation (MDR). It establishes a framework for demonstrating clinical safety and performance throughout a medical device\u2019s lifecycle, replacing previous MEDDEV guidance with more stringent requirements.<\/p>\n This guidance matters because it directly affects how medical device companies must approach clinical evidence generation. The document outlines specific expectations for clinical evaluation reports, post-market surveillance activities, and ongoing clinical data collection. Companies must demonstrate continuous monitoring of clinical performance, not just initial safety and efficacy.<\/p>\n The guidance applies to all medical device classes but places particular emphasis on higher-risk devices. It requires companies to establish systematic processes for collecting, analyzing, and acting on clinical data throughout the product lifecycle. This represents a shift from the previous approach, in which clinical evaluation was often treated as a one-time activity.<\/p>\n Non-compliance with MDCG 2019-11 requirements can result in regulatory delays, market access issues, or the withdrawal of CE marking. The guidance forms part of the MDR framework, making adherence effectively mandatory for companies selling medical devices in the European market.<\/p>\n A dedicated quality manager is not always necessary to implement MDCG 2019-11. Many companies successfully manage these requirements through existing quality personnel, external consultants, or by expanding current roles. The key is ensuring that someone with appropriate expertise oversees clinical evaluation processes and post-market surveillance activities.<\/p>\n The decision depends on several factors, including company size, product portfolio complexity, and current quality management capacity. Larger companies with multiple device types and extensive clinical data often benefit from dedicated personnel. Smaller companies may find it more cost-effective to use consultants or train existing staff.<\/p>\n What matters most is having someone who understands clinical evaluation requirements, can interpret clinical data, and can establish robust post-market surveillance systems. This person needs to coordinate among clinical affairs, regulatory, and quality functions to ensure comprehensive compliance.<\/p>\n Consider your current workload and any expertise gaps. If existing quality staff are already stretched managing other MDR requirements, additional resources may be necessary. However, this does not automatically mean hiring a full-time dedicated manager. Part-time specialists or consultants can often provide the necessary expertise more efficiently.<\/p>\n Several alternatives exist to hiring a full-time quality manager for MDCG 2019-11<\/strong> compliance. External consultants offer specialized expertise without long-term employment commitments. Many companies also expand existing roles, train current staff, or use part-time specialists to manage these requirements effectively.<\/p>\n Consulting services provide immediate access to experienced professionals who understand clinical evaluation requirements. This approach works well for smaller companies or those with limited clinical evaluation needs. Consultants can establish systems, train internal staff, and provide ongoing support as needed.<\/p>\n Training existing quality or regulatory personnel is another viable option. Many professionals can develop the necessary skills through targeted education and mentoring. This approach builds internal capability while avoiding additional headcount costs.<\/p>\n Part-time or contract specialists offer a middle-ground solution. These professionals provide dedicated expertise without full-time costs. They can focus specifically on clinical evaluation and post-market surveillance while integrating with existing quality systems.<\/p>\n Some companies establish shared resources across multiple sites or partner with other organizations to share the cost of expertise. This collaborative approach works particularly well for companies with similar product types or complementary capabilities.<\/p>\n The best approach depends on your specific circumstances, budget constraints, and long-term strategic goals. We can help you evaluate these options and determine the most suitable approach for your organization\u2019s MDCG 2019-11 compliance needs.<\/p>\n","protected":false},"excerpt":{"rendered":" Most companies don’t need dedicated quality managers for MDCG 2019-11. Discover cost-effective alternatives for clinical evaluation compliance. […]<\/p>\nDo you need a dedicated quality manager to implement MDCG 2019-11 requirements?<\/h2>\n
What are the alternatives to hiring a full-time quality manager for MDCG compliance?<\/h2>\n